基于体表面积的调整体重方案优化术前CT结肠成像-血管造影对比剂剂量
回顾性单中心研究纳入221例结直肠癌患者,比较总重量碘方案与基于体表面积的调整体重方案在术前CTC-A中的增强稳定性。结果显示调整体重方案降低了血管和肝实质增强的体重依赖性,血管显示和肝转移灶清晰度临床可接受。
要点
- 基于BSA的调整体重方案按21.74 g I/m2给药,固定注射时间30秒。
- 该方案使腹主动脉、肠系膜上/下动脉和肝实质增强的体重依赖性降低。
- 各体重组血管衰减稳定,肝实质增强中位数约57.5-61.1 HU。
诊断标准与关键数值
- 总重量方案组回归斜率:腹主动脉2.96 HU/kg,肠系膜上动脉3.98 HU/kg,肠系膜下动脉4.53 HU/kg,肝实质0.42 HU/kg。
- 调整体重方案组回归斜率:腹主动脉0.13 HU/kg,肠系膜上动脉-0.39 HU/kg,肠系膜下动脉0.22 HU/kg,肝实质-0.06 HU/kg。
- 调整体重方案组各体重分层血管衰减稳定(所有p>0.05),肝实质增强中位数约57.5-61.1 HU。
局限性
- 回顾性单中心设计。
- 样本量221例,结论需多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate whether a body surface area (BSA)-based adjusted body weight (AdBW) protocol stabilizes vascular and hepatic parenchymal enhancement during preoperative CT colonography-angiography (CTC-A).
METHODS: This retrospective single-center study included 221 consecutive patients with colorectal cancer who underwent preoperative CTC-A between January 2024 and March 2025. Examinations used either a total body weight (TBW)-based iodine protocol (600 mg I/kg; n = 113) or a BSA-based AdBW protocol (21.74 g I/m2; n = 108), both with a fixed 30-s injection duration. Contrast enhancement and contrast-to-noise ratio (CNR) were measured in the abdominal aorta (AA), superior mesenteric artery (SMA), inferior mesenteric artery (IMA), and hepatic parenchyma. Hepatic enhancement was defined as the attenuation difference between unenhanced and portal venous-phase images. Body weight-dependent variability was assessed using linear regression slopes and body weight-stratified analyses. Qualitative vascular visualization and liver metastasis conspicuity were assessed using a five-point scale by an abdominal radiologist and a colorectal surgeon.
RESULTS: Regression slopes for the TBW and AdBW protocols were 2.96 versus 0.13 HU/kg for the AA, 3.98 versus -0.39 HU/kg for the SMA, 4.53 versus 0.22 HU/kg for the IMA, and 0.42 versus -0.06 HU/kg for hepatic parenchyma, respectively. The AdBW protocol reduced body weight dependency for all enhancement parameters. In stratified analyses, vascular attenuation remained stable across all body weight groups with AdBW dosing (all p > 0.05). Hepatic enhancement was also more consistent, with median values maintained at approximately 57.5-61.1 HU. Qualitative assessment showed that vascular visualization and liver metastasis conspicuity remained clinically acceptable with the AdBW protocol.
CONCLUSION: BSA-based AdBW dosing reduced body habitus-dependent variability in vascular and hepatic enhancement during preoperative CTC-A.
引用
- Miyazaki H, Hirotaki K, Takahashi K, et al. Optimization of contrast medium dosing using a body surface area-based protocol for preoperative CT colonography-angiography. Abdom Radiol (NY). 2026. PMID: 42517900. doi:10.1007/s00261-026-05704-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。